德谷门冬双胰岛素治疗初诊2型糖尿病的疗效与安全性

Efficacy and Safety of Degu Aspartic Double Insulin in the Treatment of Newly Diagnosed Type 2 Diabetes

目的评价德谷门冬双胰岛素(IDegAsp)治疗初诊2型糖尿病(T2DM)疗效和安全性。方法选取2020年6月—2021年3月该院初诊T2DM患者80例,依据随机数表法按1∶1的比例分为IDegAsp组和口服降糖药物治疗组(OADs组),每组40例,观察治疗12周后空腹血糖(fasting plasma glucose,FPG)、餐后2 h血糖(2 hours postprandial blood glucose,2 hPG)、糖化血红蛋白(glycosylated hemoglobin,HbA1c)水平、低血糖事件发生率及体质指数变化。结果12周后,IDegAsp组FPG[(6.17±0.49)mmol/L vs(9.41±1.23)mmol/L],2 hPG[(7.46±0.84)mmol/L vs(14.90±1.86)mmol/L],HbA1c[(6.50±0.54)%vs(9.09±0.76)%]均低于同组治疗前,差异有统计学意义(P<0.05);OADs组FPG[(6.47±0.60)mmol/L vs(9.22±1.01)mmol/L],2 hPG[(7.18±1.04)mmol/L vs(14.10±1.91)mmol/L],HbA1c[(6.85±0.54)%vs(8.90±0.82)%]均低于同组治疗前,差异有统计学意义(P<0.05)。治疗后IDegAsp组FPG、HbA1c均低于OADs组,差异有统计学意义(P<0.05),两组间的2 hPG、体质量变化及低血糖发生率差异无统计学意义(P>0.05)。结论IDegAsp治疗初诊血糖较高的T2DM患者降糖疗效优于口服药物,低血糖发生率低,体质量无明显增加,为糖尿病治疗提供了新选择。

Objective To evaluate the efficacy and safety of IDegAsp in the treatment of newly diagnosed type 2 diabetes(T2DM).Methods A total of 80 patients with T2DM who were newly diagnosed in the hospital from June 2020 to March 2021 were selected.According to the random number table method,they were divided into IDegAsp group and oral hypoglycemic drug treatment group(OADs group)at a ratio of 1:1,with 40 cases in each group.Observed the fasting plasma glucose(FPG),2 h postprandial blood glucose(2 hPG),glycosylated hemoglobin(HbA1c)levels,the incidence of hypoglycemia and the changes in body mass index after 12 weeks of treatment.Results After 12 weeks,FPG[(6.17±0.49)mmol/L vs(9.41±1.23)mmol/L],2 hPG[(7.46±0.84)mmol/L vs(14.90±1.86)mmol/L],HbA1c[(6.50±0.54)%vs(9.09±0.76)%]in IDegAsp group were lower than before treatment in the same group,the difference was statistically significant(P<0.05).OADs group FPG[(6.47±0.60)mmol/L vs(9.22±1.01)mmol/L],2 hPG[(7.18±1.04)mmol/L vs(14.10±1.91)mmol/L],HbA1c[(6.85±0.54)%vs(8.90±0.82)%]were lower than the same group before treatment,the difference was statistically significant(P<0.05).After treatment,FPG and HbA1c in IDegAsp group were lower than those in OADs group,the difference was statistically significant(P<0.05).There was no statistically significant difference in 2 hPG,weight change and incidence of hypoglycemia between the two groups(P>0.05)Conclusion IDegAsp has better anti-diabetic effect in the treatment of newly diagnosed T2DM patients with high blood glucose than oral drugs,the incidence of hypoglycemia is low,and there is no significant increase in body weight,which provides a new option for the treatment of diabetes.